Keigo Shibayama

8.3k citations
228 papers · 6.1k indexed · h-index 39

Keigo Shibayama

224 papers receiving 5.9k citations

Peers

Keigo Shibayama
Comparison fields: 5 of 137
  • Molecular Medicine 3.0k
  • Endocrinology 1.5k
  • Applied Microbiology and Biotechnology 435
  • Microbiology 655
  • Pollution 707
Replace Sebastián Albertí with:
Sebastián Albertí Spain
Yin-Ching Chuang Taiwan
Jacob Strahilevitz Israel
Yoshichika Arakawa Japan
Jesús Blázquez Spain
Seok Hoon Jeong South Korea
Tyrone L. Pitt United Kingdom
K. J. Towner United Kingdom
Hongwei Zhou China
Niels Frimodt‐Møller Denmark
Keigo Shibayama relative to Sebastián Albertí Spain Sebastián Albertí's profile →
Citations per field
00.5×1.5×
Sebastián Albertí · 1×
Citations per year

Countries citing papers authored by Keigo Shibayama

Since Specialization
Citations

This map shows the geographic impact of Keigo Shibayama's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Keigo Shibayama with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Keigo Shibayama more than expected).

Fields of papers citing papers by Keigo Shibayama

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Keigo Shibayama. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Keigo Shibayama. The network helps show where Keigo Shibayama may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Keigo Shibayama, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Keigo Shibayama Line = papers co-authored together Keigo Shibayama links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1 20250
2 20243
3 20241
4 20231
5 20215
6 202140
7 202120
8 202114
9 20211
10 202027
11 201836
12 201721
13 20148
14 201421
15 20138
16 201330
17 20127
18 20117
19
20040
20 2003171

About Keigo Shibayama

Keigo Shibayama is a scholar working on Molecular Medicine, Endocrinology and Microbiology, having authored 228 papers that have together received 6.1k indexed citations. Recurring topics across this work include Antibiotic Resistance in Bacteria (75 papers), Pneumonia and Respiratory Infections (36 papers), Mycobacterium research and diagnosis (29 papers), Helicobacter pylori-related gastroenterology studies (29 papers), Streptococcal Infections and Treatments (26 papers), Bacterial Infections and Vaccines (24 papers), Enterobacteriaceae and Cronobacter Research (19 papers) and Bacterial biofilms and quorum sensing (18 papers). The work is most often cited by research in Molecular Medicine (3.0k citations), Endocrinology (1.5k citations) and Applied Microbiology and Biotechnology (435 citations). Keigo Shibayama has collaborated with scholars based in Japan, United States and Vietnam. Frequent co-authors include Yoshichika Arakawa, Naohiro Shibata, Hiroshi Kurokawa, Tetsuya Yagi, Kunikazu Yamane, Satowa Suzuki, Haru Kato, Jun‐ichi Wachino, Kouji Kimura and Yohei Doi. Their work appears in journals such as Proceedings of the National Academy of Sciences, The Lancet and PLoS ONE.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026